Last reviewed · How we verify
NCT05826444: mCAV
Microvascular Cardiac Allograft Vasculopathy Trial
trial testing Echocardiography in Cardiac Allograft Vasculopathy in 50 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | German Heart Institute |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 1 October 2022 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Echocardiography
- Magnetic resonance imaging
- Magnetocardiography
- Histology — full drug profile →
- Genetics
- calcium signaling
- IMR
- Angio-IMR
Conditions studied
- Cardiac Allograft Vasculopathy — all drugs for Cardiac Allograft Vasculopathy →
Sponsor
German Heart Institute
Who can join
Eligibility, any sex, with Cardiac Allograft Vasculopathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the mCAV study is a comprehensive characterization of the genetic, morphological and functional phenotype of isolated microvascular graft vasculopathy (mCAV) after orthotopic heart transplantation (OHT). The utilized methods include dynamic echocardiography, magnetic resonance imaging, invasive microvascular resistance measurements, histology, cellular calcium-signaling and magnetocardiography as well as molecular genetic expression analysis (miRNA based).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05826444
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Echocardiography
Trials testing the same drug.
- NCT06863402 — Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype · Phase 2 · recruiting
- NCT07372859 — Women's Heart: Impact of Ultra-endurance and Hormonal Profile on Cardiac and Systemic Inflammatory Parameters in Female · NA · not yet recruiting
- NCT06434064 — Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advan · Phase 2 · recruiting
- NCT06871410 — Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia · Phase 1 · recruiting
- NCT07375433 — Heart Failure With Preserved Ejection Fraction in Patients With Сhronic Obstructive Pulmonary Disease: Clinical Course a · recruiting
Other German Heart Institute trials
Trials by the same sponsor.
- NCT07320560 — Personalized Atrial Fibrillation Ablation Guided by Non-Invasive Global Mapping · NA · recruiting
- NCT07185100 — Determination of the Prevalence of Unrecognized Heart Failure Among Patients at Risk in Urban Areas Across Germany Using · recruiting
- NCT06246188 — Use of Stress-CMR Using Regadenoson and GE-267 in Adult Patients with Known or Suspected Coronary Artery Disease · not yet recruiting
- NCT06689098 — Magnetocardiography as a Diagnostic Screening Tool for Myocarditis and Other Types of Cardiomyopathy · completed
- NCT05422859 — Mobile and Digital Application in Heart Failure Networks Berlin/Brandenburg · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05826444 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by German Heart Institute
- Last refreshed: 12 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05826444.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing